Literature DB >> 32474689

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.

Mei Qiu1, Shu-Yan Liu2, Jin-Song Gu3, Kai-Kai Li4, Ling-Lin Li5, Liang-Liang Ding6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32474689     DOI： 10.1007/s12020-020-02359-5

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  3 in total

1.  Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Mei Qiu; Liang-Liang Ding; Ze-Lin Zhan; Hai-Rong Zhou
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-26       Impact factor: 5.555

2.  Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.

Authors:  Rong Chang; Shu-Yan Liu; Li-Min Zhao
Journal:  Medicine (Baltimore)       Date:  2021-11-24       Impact factor: 1.817

3.  Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Li-Min Zhao; Ze-Lin Zhan; Jie Ning; Mei Qiu
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.